NLSP NLS Pharmaceutics
- 0.1380
- +0.0020+1.47%
- 0.1383
- +0.0003+0.22%
NLS Pharmaceutics News
NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | 6-K: Report of foreign private issuer (related to financial reporting)
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | D: Filing D
NLS Pharmaceutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lind Global Fund II LP(9.9%),Lind Global Partners II LLC(9.9%), etc.
NLS Pharmaceutics | 424B5: Prospectus
NLS Pharmaceutics | 6-K: Report of foreign private issuer (related to financial reporting)
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | 6-K: Report of foreign private issuer (related to financial reporting)
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-YA II PN, Ltd.(9.99%),YA Global Investments II (U.S.), LP(9.99%), etc.
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
NLS Pharmaceutics | 6-K: Report of foreign private issuer (related to financial reporting)
NLS Pharmaceutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Analysis
Price Target
No Data
